- Home
- SND vs ZNTL Comparison
SND vs ZNTL Comparison
Compare SND & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SND | ZNTL |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.3M | 118.3M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SND | ZNTL |
|---|---|---|
| Price | $4.02 | $1.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.87 |
| AVG Volume (30 Days) | ★ 549.4K | 500.8K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $335,471,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.35 | ★ N/A |
| Revenue Growth | ★ 18.98 | N/A |
| 52 Week Low | $1.76 | $1.01 |
| 52 Week High | $4.51 | $3.72 |
Technical Indicators
Market Signals| Indicator | SND | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 67.79 | 49.05 |
| Support Level | $3.29 | $1.34 |
| Resistance Level | $4.51 | $1.45 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 73.56 | 52.94 |
Price Performance
Historical ComparisonAbout SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.